Clinical trials: Liver Graft Dysfunction
Chronic Hepatitis B
A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.
A clinical study evaluating the pharmacokinetic characteristics and safety of AHB-137 injection in participants with mild to moderate liver dysfunction and those with normal liver function.
- Trial name
- NCT07600788
- Testing
- AHB-137 injection
- Where
- 5 sites in China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Ausper Biopharma Co., Ltd.
Coronary Artery Disease of Significant Bypass Graft, Metabolic Dysfunction-associated Fatty Liver Disease
Positive Association of US-FLI With the Severity of CAD
As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD).
- Conditions
- Coronary Artery Disease of Significant Bypass Graft, Metabolic Dysfunction-associated Fatty Liver Disease, SYNTAX Score, Ultrasonography
- Trial name
- NCT06541132
- Testing
- Observational study without human intervention
- Where
- China
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Chongqing Medical University
Hepatic Failure, Liver Failure
Cardiox Liver Function Test Pivotal Trial
Performance evaluation of LFT Dye Monitor System using ICG - plasma disappearance rate value (PDR) to assess liver function in normal patients as well as in patients with mild to severe hepatic impairment compared to manual Serum…
- Trial name
- LFT-0002 (NCT02552901)
- Testing
- 0.1 mg/kg ICG Dose, 0.5 mg/kg ICG dose
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Cardiox Corporation